文献速递临床试验与 GCP流行病学与生物统计

预防单胎妊娠高危女性自发性早产的干预措施:系统评价与网状Meta分析

Interventions to prevent spontaneous preterm birth in women with singleton pregnancy who are at high risk: systematic review and network meta-analysis.
PubMed 文献 · BMJ · 2022-02-15

该系统评价与贝叶斯网状Meta分析纳入61项随机对照试验(17273名孕妇),比较卧床休息、宫颈环扎、宫颈托、鱼油、营养补充、孕酮、预防性抗生素等干预措施预防单胎妊娠且有自发性早产史或宫颈短的高危女性自发性早产的效果。以安慰剂或无治疗为对照,阴道孕酮与早产<34周较少相关(OR 0.50,95%CI 0.34至0.70,高确定性证据),且是唯一对围产期死亡显示明确获益的治疗(OR 0.66,95%CI 0.44至0.97,中等确定性)。结论认为阴道孕酮应被视为这类女性的首选预防治疗。

要点

  • 阴道孕酮与安慰剂或无治疗相比减少早产<34周(OR 0.50,95%CI 0.34至0.70,高确定性证据)。
  • 阴道孕酮是唯一对围产期死亡显示明确获益的治疗(OR 0.66,95%CI 0.44至0.97,中等确定性)。
  • 仅孕酮治疗与新生儿呼吸窘迫综合征、脓毒症、坏死性小肠结肠炎及新生儿重症监护入院减少相关。

核心结论

  • 阴道孕酮应被视为因自发性早产史或宫颈短而被识别为自发性早产风险的单胎妊娠女性的首选预防治疗。
  • 未来随机对照试验应以阴道孕酮为对照,以识别更好的治疗或联合治疗。

研究设计与样本

  • 系统评价与贝叶斯网状Meta分析,检索Cochrane妊娠和分娩组试验数据库、Cochrane中央对照试验注册库、Medline、Embase、CINAHL、相关期刊、会议论文集及在研试验注册库,无语言或日期限制。
  • 纳入因自发性早产史或宫颈短而处于自发性早产高风险的孕妇的随机对照试验。
  • 共61项试验(17273名孕妇)为至少一个结局的分析提供数据;早产<34周分析纳入40项试验(13310名孕妇),围产期死亡分析纳入30项试验(12119名孕妇)。

主要发现

  • 以安慰剂或无治疗为对照,阴道孕酮与早产<34周较少相关(OR 0.50,95%CI 0.34至0.70,高确定性证据)。
  • Shirodkar宫颈环扎效应量最大(OR 0.06,95%CI 0.00至0.84),但证据确定性低。
  • 17OHPC(OR 0.68,95%CI 0.43至1.02,中等确定性)、宫颈托(OR 0.65,95%CI 0.39至1.08,中等确定性)和鱼油或omega 3(OR 0.30,95%CI 0.06至1.23,中等确定性)与安慰剂或无治疗相比可能减少早产<34周。
  • 以安慰剂或无治疗为对照,阴道孕酮是唯一对围产期死亡显示明确获益的治疗(OR 0.66,95%CI 0.44至0.97,中等确定性);17OHPC(OR 0.78,95%CI 0.50至1.21)、McDonald宫颈环扎(OR 0.59,95%CI 0.33至1.03)和未指定类型宫颈环扎(OR 0.77,95%CI 0.53至1.11)可能降低围产期死亡 rates,但可信区间不能排除伤害的可能性(均为中等确定性)。
  • 与对照相比,仅孕酮治疗与新生儿呼吸窘迫综合征、新生儿脓毒症、坏死性小肠结肠炎及新生儿重症监护入院减少相关。

关键数值与推荐

  • 早产<34周:阴道孕酮OR 0.50(95%CI 0.34至0.70),高确定性证据;Shirodkar宫颈环扎OR 0.06(95%CI 0.00至0.84),低确定性证据;17OHPC OR 0.68(95%CI 0.43至1.02),中等确定性;宫颈托OR 0.65(95%CI 0.39至1.08),中等确定性;鱼油或omega 3 OR 0.30(95%CI 0.06至1.23),中等确定性。
  • 围产期死亡:阴道孕酮OR 0.66(95%CI 0.44至0.97),中等确定性;17OHPC OR 0.78(95%CI 0.50至1.21),中等确定性;McDonald宫颈环扎OR 0.59(95%CI 0.33至1.03),中等确定性;未指定类型宫颈环扎OR 0.77(95%CI 0.53至1.11),中等确定性。
  • 分析7项母体结局和11项胎儿结局,符合已发表的早产研究核心结局集。

临床怎么用

  • 作者结论认为阴道孕酮应被视为因自发性早产史或宫颈短而被识别为自发性早产风险的单胎妊娠女性的首选预防治疗。
  • 作者建议未来随机对照试验应以阴道孕酮为对照,以识别更好的治疗或联合治疗。

局限性

  • Shirodkar宫颈环扎的效应量基于低确定性证据。
  • 17OHPC、宫颈托和鱼油或omega 3减少早产<34周的证据为中等确定性。
  • 17OHPC、McDonald宫颈环扎和未指定类型宫颈环扎对围产期死亡的可能获益为中等确定性,且可信区间不能排除伤害的可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the efficacy of bed rest, cervical cerclage (McDonald, Shirodkar, or unspecified type of cerclage), cervical pessary, fish oils or omega fatty acids, nutritional supplements (zinc), progesterone (intramuscular, oral, or vaginal), prophylactic antibiotics, prophylactic tocolytics, combinations of interventions, placebo or no treatment (control) to prevent spontaneous preterm birth in women with a singleton pregnancy and a history of spontaneous preterm birth or short cervical length. DESIGN: Systematic review with bayesian network meta-analysis. DATA SOURCES: The Cochrane Pregnancy and Childbirth Group's Database of Trials, the Cochrane Central Register of Controlled Trials, Medline, Embase, CINAHL, relevant journals, conference proceedings, and registries of ongoing trials. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials of pregnant women who are at high risk of spontaneous preterm birth because of a history of spontaneous preterm birth or short cervical length. No language or date restrictions were applied. OUTCOMES: Seven maternal outcomes and 11 fetal outcomes were analysed in line with published core outcomes for preterm birth research. Relative treatment effects (odds ratios and 95% credible intervals) and certainty of evidence are presented for outcomes of preterm birth <34 weeks and perinatal death. RESULTS: Sixty one trials (17 273 pregnant women) contributed data for the analysis of at least one outcome. For preterm birth <34 weeks (40 trials, 13 310 pregnant women) and with placebo or no treatment as the comparator, vaginal progesterone was associated with fewer women with preterm birth <34 weeks (odds ratio 0.50, 95% credible interval 0.34 to 0.70, high certainty of evidence). Shirodkar cerclage showed the largest effect size (0.06, 0.00 to 0.84), but the certainty of evidence was low. 17OHPC (17α-hydroxyprogesterone caproate; 0.68, 0.43 to 1.02, moderate certainty), vaginal pessary (0.65, 0.39 to 1.08, moderate certainty), and fish oil or omega 3 (0.30, 0.06 to 1.23, moderate certainty) might also reduce preterm birth <34 weeks compared with placebo or no treatment. For the fetal outcome of perinatal death (30 trials, 12 119 pregnant women) and with placebo or no treatment as the comparator, vaginal progesterone was the only treatment that showed clear evidence of benefit for this outcome (0.66, 0.44 to 0.97, moderate certainty). 17OHPC (0.78, 0.50 to 1.21, moderate certainty), McDonald cerclage (0.59, 0.33 to 1.03, moderate certainty), and unspecified cerclage (0.77, 0.53 to 1.11, moderate certainty) might reduce perinatal death rates, but credible intervals could not exclude the possibility of harm. Only progesterone treatments are associated with reduction in neonatal respiratory distress syndrome, neonatal sepsis, necrotising enterocolitis, and admission to neonatal intensive care unit compared with controls. CONCLUSION: Vaginal progesterone should be considered the preventative treatment of choice for women with singleton pregnancy identified to be at risk of spontaneous preterm birth because of a history of spontaneous preterm birth or short cervical length. Future randomised controlled trials should use vaginal progesterone as a comparator to identify better treatments or combination treatments. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020169006.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Care A, Nevitt SJ, Medley N, et al. Interventions to prevent spontaneous preterm birth in women with singleton pregnancy who are at high risk: systematic review and network meta-analysis. BMJ. 2022. PMID: 35168930. doi:10.1136/bmj-2021-064547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。